




THE **2019** ANNUAL MEETING OF THE LEBANESE PULMONARY SOCIETY

LE CONGRES ANNUEL **2019** DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



14 CME CREDITS

slpsleb.org

May 2 - 4, 2019 | Phoenicia Hotel, Beirut - Lebanon



Reach. Treat. Benefit



THE **ONLY EXTRAFINE** ICS/LABA COMBINATION
APPROVED IN **ASTHMA** AND COPD





THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**

LE **CONGRES ANNUEL 2019**
DE LA **SOCIÉTÉ LIBANAISE DE PNEUMOLOGIE**



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon



Dear Friends and Colleagues,

It is with a great pleasure that I invite you all to the Lebanese Pulmonary Society Annual Meeting in May 2-4, 2019.

This year like the past years, we will have eminent local and international speakers presenting in addition to the state of the art workshops.

The success I foresee relies greatly on the international collaboration with the AFLP (Association Franco-Libanaise de Pneumologie) and every single attendee.

Our joint efforts lead to a global dimension enriched by the speakers' expertise in the fields of Pulmonary Medicine and related sciences.

I am confident that this educational opportunity will be only matched by the social entertainment offered by our enchanting Beirut and beautiful Lebanon.

I am looking forward to meeting every single one of you.

Chers Amis et Collègues,

C'est avec un immense plaisir que je vous invite à participer au congrès annuel de la Société Libanaise de Pneumologie qui se tiendra à Beyrouth du 2 au 4 mai 2019.

Cette année, comme par les années précédentes, d'éminents conférenciers locaux et internationaux présenteront les dernières nouveautés dans notre domaine ainsi que des ateliers interventionnels.

Le succès que je prévois repose en grande partie sur la collaboration avec l'AFLP (Association Franco-Libanaise de Pneumologie) et chaque participant individuellement.

Nos efforts communs conduisent à une dimension globale enrichie par l'expertise des intervenants dans les domaines de la pneumologie et des autres spécialités.

Je suis certain que cette opportunité éducative serait en grande partie appuyée par le charme de notre cité Beyrouth et de notre agréable Liban.

En attendant de vous accueillir, veuillez agréer mes salutations les plus sincères.

Salah Zeineldine, MD FACP

President, Lebanese Pulmonary Society

Président de la Société Libanaise de Pneumologie



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**
LE CONGRES ANNUUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

PRESIDENT OF THE CONGRESS
PRESIDENT OF THE LEBANESE PULMONARY SOCIETY

- Salah Zeineldine

SCIENTIFIC COMMITTEE

- Zeina Aoun Bacha Chair
- Diana Sassine Co-Chair
- Walid Alaeddine Member
- Fadi Antoun Member
- Ghada Bourjeily Member
- Hassan Chami Member
- Georges Chebly Member
- Pierre Edde Member
- Carine Harmouche Member
- Georges Juvelekian Member
- Georges Khayat Member
- Carole Youakim Member
- Youssef Zein Member

ORGANIZING COMMITTEE

- Celine Baaklini Chair
- Hilmi Darwich Co-Chair
- Rabih Abou Shami Member
- Samir Challita Member
- Dany Gaspard Member
- Jamal Kabbani Member
- Richard Timeri Member
- Joe Zein Member
- Georgette Mouannes Member



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**

LE CONGRES ANNUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



الجمعية اللبنانية للأمراض الصدرية
THE LEBANESE PULMONARY SOCIETY

May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

SPEAKERS



Ghada Bourjeily, MD
Associate Professor of
Medicine Warren Alpert
Medical School of Brown
University
USA



Imad Bouaki, MD
Director of the Pulmonary Critical
Care Fellowship Program
Chair of the ICU Committee
Associate Program Director of
Internal Medicine Residency
American University of Beirut
Lebanon



Fadi Antoun, MD
Pulmonology
Referent Tuberculosis
Hospital Practitioner CHU
Kremlin Bicetre
Paul Brousse Hospital
France



Olivier Brugiere, MD, PhD
Associate Professor
Hospital Practitioner
Pulmonary B & Pulmonary
Transplant Service
France



**Françoise Le Pimpec-Barthes,
MD, PhD**
Thoracic Surgery & Pulmonary
Transplantation
Faculty Paris Descartes
France



Hassan Chami, MD
Specialist in Pulmonary,
Critical Care & Sleep Medicine
Assistant Professor of Clinical
Medicine
American University of Beirut
Lebanon



Alia Bazy-Asaad, MD
Associate Professor of
Pediatrics
(Pulmonology)
Yale School of Medicine
USA



Pr. Francis Couturaud
Department of Medicine
Internal & Pulmonary
EA Director
Cavale Blanche Hospital
CHRU of Brest
France



Jamil Borgi, MD
Assistant Professor of
Clinical Surgery
American University of Beirut
Medical Center
Lebanon



Georges Dabar, MD, FCCP
Pulmonary & Critical Care
Hotel Dieu de France
Assistant Professor
Saint Joseph University
Lebanon



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**

LE CONGRES ANNUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon



Hilmi Darwiche, MD
Chest physician
University Claude Bernard
President of North Lebanese
Pulmonary Society
Member of Executive Committee
of Lebanese pulmonary Society
Lebanon



Jesus Gonzalez, MD
Professor at Sorbonne University
Faculty of Medicine
Pulmonology
Hospital Practitioner
Head of the SSR Respiratory
Functional Unit
France



Fayssal El Hussein, MD
Pulmonology
Cochin Hospital
AP - HP
France



Carine Harmouche, MD
Instructor at USJ
School of Medicine
Pulmonary-Critical Care Physician
Responsible of Inhalation Unit
Hotel-Dieu de France
Lebanon



Fadi El Karak, MD, MSc
Hematologist & Oncologist
Chief of the Hematology
Medical Oncology
Service Position
Bellevue Medical Center
Lebanon



Rim Hjej, Dr. rer. nat
Project Leader in Department
of Pediatrics
University Hospital Münster
Expertise in Diagnosis of Primary
Ciliary Dyskinesia
Germany



Elie Fadel, MD, PhD
Department of Thoracic &
Vascular Surgery &
Heart Lung Transplantation
Marie Lannelongue Hospital
France



Ahmad Husari, MD
Professor of Internal Medicine
Director of the Medical Intensive
Care Unit
Director of Faculty Affairs
American University of Beirut
Lebanon



Cendrine Godet, MD
Medical Doctor
Specialised in Pulmonary
Infectious Disease Service
La Milétrie Hospital
France



Elvis M Irusen, MB ChB, FCP(SA)
Pulmonology, PhD, FCCP
Pulmonology & Critical Care
Department of Medicine
Stellenbosch University
Tygerberg Hospital
South Africa



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**

LE CONGRES ANNUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon



Georges Juvelekian, MD, FCCP, D'ABSM
Head Division of Pulmonary
Critical Care & Sleep Medicine
St George Hospital
Assistant Prof of Clinical
Medicine at Balamand University
Lebanon



Olivier Sitbon, MD, PR
Professor of Respiratory Medicine
Pulmonary Hypertension Reference
Center Pulmonary & Intensive Care
South Paris University
Kremlin Bicetre
France



Marc Miravittles, MD
Investigator Senior
Senior Researcher
Pneumology
Vall d'Hebron University Hospital
Spain



Arafat Tfayli, MD
Professor of Clinical Medicine
Director of Research at NK Basile
Cancer Institute
AUBMC
Lebanon



Rima Nakkash, MPH, DrPH
Associate Professor
Health Promotion
Community Health Department
Faculty of Health Sciences
American University of Beirut
Lebanon



Carole Youakim, MD
Pulmonary & Allergy Specialist
Past President of LPS
Head of Pulmonary Department
Mount Lebanon Hospital
Lebanese University Medical School
LAU School of Medicine
Lebanon



Martino Pengo MD, PhD
Sleep Disorder Centre
Department of Cardiovascular
Neural & Metabolic Sciences
IRCCS Auxologico Institute
Italy



Joe Zein, MD
Staff Physician Respiratory
Institute Cleveland Clinic
USA



Moussa Riachi, MD, PR, PU - PH
Pulmonologist & Critical Care
Physician - HDF
Associate Professor of
Respiratory Medicine at the
Faculty of Medicine
Saint Joseph University
Lebanon



Salah Zeineldine, MD FACP
President of the Lebanese
Pulmonary Society
Associate Professor of Clinical
Medicine
Internal Medicine AUB - Faculty
of Medicine & Medical Center
Lebanon



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**
LE CONGRES ANNUEL 2019
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

THURSDAY MAY 02, 2019

14:00 - 15:00 Registration & Welcome Coffee

15:00 - 16:15 Diaphragmatic Disorders

Moderators: Georges Chebli - Andre Fargelat - Ziad Mansour

15:00 - 15:25	Diaphragmatic Disorders Clinical Presentation & Assessment	Salah Zeineldine
15:25 - 15:50	Medical Care of Diaphragmatic Disorders	Jesus Gonzales
15:50 - 16:15	Surgical Care of Diaphragmatic Disorders	Françoise Le Pimpec Barthes

16:15 - 17:00 Asthma Control Prevalence in MEA: ESMAA Results
Symposium Sponsored by Astra Zeneca Salah Zeineldine

17:00 - 17:20 Coffee Break

17:20 - 18:05 New Real-Life Data and Perspectives in Severe Asthma Patients
Symposium Sponsored by Novartis Georges Dabbar
Hassan Chami



THE **2019** ANNUAL MEETING
OF THE LEBANESE PULMONARY SOCIETY
LE CONGRES ANNUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

FRIDAY MAY 03, 2019

08:00 Registration

09:00 - 10:15 Updates on Respiratory Infections

Moderators: Ali Ben Kheder - Hiam Yaacoub - Youssef Zein

09:00 - 09:25	Update on Latent Tuberculosis Treatment	Fadi Antoun
09:25 - 09:50	Challenges of Invasive Aspergillosis in Non-Neutropenic Patients	Olivier Brugière
09:50 - 10:15	Chronic Aspergillosis in Immunocompetent Patient: Is it Different?	Cendrine Godet

10:15 - 10:30 Coffee Break

10:30 - 11:15 New Perspectives in Idiopathic Pulmonary Fibrosis Management
Symposium Sponsored by Boehringer Ingelheim Imad Bou Akl

11:15 - 12:30 Updates in Sleep Medicine

**Moderators: Dani Abou Abdallah - Marie-Louise Coussa Koniski
Jamal Kabbani - Franck Soyez**

11:15 - 11:40	OSA and Cardiovascular Outcomes	Martino Pengo
11:40 - 12:05	Sex Differences in Sleep Disordered Breathing	Ghada Bourjeily
12:05 - 12:30	Phenotyping Sleep Apnea	Martino Pengo

12:30 - 12:55 Opening Ceremony

National Anthem
Master of Ceremony
Dr. Celine Baaklini

12:30 - 12:35 The Address of the President of LPS
Dr. Salah Zeineldine

12:35 - 12:40 The Address of the President of AFLP
Dr. Richard Timery

12:40 - 12:45 The Address of SPLF Representative
Dr. Franck Soyez

12:45 - 12:50 The Address of the Lebanese Order of Physicians
Prof. Raymond Sayegh

12:50 - 12:55 The Address of the President of the Lebanese Republic
General Michel Aoun



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**
LE CONGRES ANNUEL 2019
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

FRIDAY MAY 03, 2019

12:55 - 13:45 Panel Discussion

Moderator: Najat Saliba

12:55 - 13:45	The Increasingly Local Evidence of the Association Between Air Pollution and our Deteriorating Health	Mazen Malkawi Hyam Mallat Issam Lakkis Tharwat Mokalled Zeina Aoun
---------------	---	--

13:45 - 14:45 Lunch Break

Moderator: Celine Baaklini

14:45 - 15:30	The RIGHT Treatment for the RIGHT Patient: Evidence Based Management of COPD <i>Symposium Sponsored by GlaxoSmithKline</i>	Elvis Irusen
---------------	---	--------------

15:30 - 17:10 Thromboembolic Disease

Moderators: Pierre Edde - Paul Morin - Jamal Omeiss - Carole Youakim

15:30 - 15:55	Massive Pulmonary Embolism: Diagnosis and Treatment Options	Francis Couturaud
15:55 - 16:20	Angioplasty for the Management of Inoperable Chronic Thromboembolic Pulmonary Hypertension	Elie Fadel
16:20 - 16:45	Endarterectomy: Lebanese Experience	Jamil Borgi
16:45 - 17:10	CTEPH, What are Medical Therapeutic Options?	Olivier Sitbon
Moderator: Imad Bou Akl		
17:10 - 18:10	PAH: Staying Ahead Of Disease Progression <i>Symposium Sponsored by Actelion</i>	Olivier Sitbon

18:10 - 18:25 Coffee Break

18:25 - 19:40 Personal Experience in Sleep Disorders and Respiratory Failure

Moderators: Samir Challita - Kamel Falha - Bernard Pigearias

18:25 - 18:50	Telemedicine in Sleep Management	Fayssal El Husseini
18:50 - 19:15	Talking Masks in Ventilated Patients	Moussa Riachi
19:15 - 19:40	Survey on Sleep Disorders in Beirut	Hassan Chami



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**
LE CONGRES ANNUEL 2019
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

SATURDAY MAY 04, 2019

08:30 Registration

09:00 - 10:15 Smoking Health Effect

Moderators: Antoine Abou Samra - Francis Khoury - Ali Akil

09:00 - 09:25 Waterpipe Tobacco Smoking: Prevalence, Harms and Policy Regulation Rima Nakkash

09:25 - 09:50 E Cigarettes and Alternatives Ahmad Husari

09:50 - 10:15 Smoking and Pregnancy Ghada Bourjeily

Moderator: Celine Baaklini

10:15 - 11:00 SPIOLTO: An Advance IN COPD Care, Based On Strong Roots
Symposium Sponsored by Boehringer Ingelheim Carole Youakim

11:00 - 11:15 Coffee Break

11:15 - 12:30 Asthma and Diseases of Prematurity: A Bird's Eye View

Moderators: Adèle Gemayel - Carla Irani - Richard Timery - Paul Henry Torbey

11:15 - 11:40 Overview of Asthma in Adolescents Alia Bazy-Asaad

11:40 - 12:05 Asthma and Obesity Joe Zein

12:05 - 12:30 Pulmonary Outcomes in Adults who were Born Preterm Alia Bazy-Asaad

Moderator: Zeina Aoun

12:30 - 13:15 Update on COPD Guidelines and Implications for Clinical Practice
Symposium Sponsored by Novartis Marc Miravittles

13:15 - 14:15 Lunch Break

Moderator: Mireille Sfeir

14:15 - 15:00 Paradigm Shift in Asthma Management: What Does the Evidence Show us?
Symposium Sponsored by GlaxoSmithKline Elvis Irušen



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**
LE CONGRES ANNUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

SATURDAY MAY 04, 2019

15:00 - 16:40 Lung Cancer Session

Moderators: Samer Abi Khalil - Rabih Abou Shami - Youssef ElFar
Ola Mazboudi

15:00 - 15:25	Lung Cancer Screening: What have we Learned?	Georges Juvelekian
15:25 - 15:50	Management of Pulmonary Nodules	Carine Harmouche
15:50 - 16:15	Immunotherapy in Metastatic NSCLC	Fadi El Karak
16:15 - 16:40	Shortfalls of Immunotherapy	Arafat Tfayli

16:40 - 16:55 Coffee Break

16:55 - 18:05 Launching of National Registry Session

16:55 - 17:10	Pulmonary Hypertension National Register Launching	Imad Bou Akl
17:10 - 17:25	Interstitial Disease National Registry Launching	Georges Dabar
17:25 - 17:35	National COPD Register Launching	Hilmi Darwiche
17:35 - 18:05	Primary Ciliary Dyskinesia National Screening and Registry Launching	Rim Hjeij

PARALLEL SESSION

ROOM B

16:55 - 18:05 BEST Poster Discussions

18:05 - 18:25 Award Announcement and Congress Closure



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**
LE CONGRES ANNUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

JEUDI 02 MAI, 2019

14:00 - 15:00 Inscription et Café d'Accueil

15:00 - 16:15 Troubles Diaphragmatiques

Modérateurs: Georges Chebli - Andre Fargelat - Ziad Mansour

15:00 - 15:25	Présentation Clinique et Évaluation des Troubles Diaphragmatiques	Salah Zeineldine
15:25 - 15:50	Evaluation Physiologique de la Dysfonction Diaphragmatique et Traitement Medical	Jesus Gonzales
15:50 - 16:15	Soins Chirurgicaux des Troubles Diaphragmatiques	Françoise Le Pimpec Barthes

16:15 - 17:00 Prevalence du Controle de L'Asthme au Moyent Orient: Résultats de ESMAA
Symposium Sponsorisé par Astra Zeneca

Salah Zeineldine

17:00 - 17:20 Pause-Café

17:20 - 18:05 Données de Vie Réelle et Nouvelles Perspectives dans la Prise en Charge de l'Asthme Sévère.
Symposium Sponsorisé par Novartis

Georges Dabbar
Hassan Chami



THE **2019 ANNUAL MEETING**
OF THE LEBANESE PULMONARY SOCIETY

LE CONGRES ANNUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

VENDREDI 03 MAI, 2019

08:00 Inscription

09:00 - 10:15 Mises à Jour sur les Infections Respiratoires

Modérateurs: Ali Ben Kheder - Hiam Yaacoub - Youssef Zein

09:00 - 09:25	Mise à Jour sur le Traitement de la Tuberculose Latente	Fadi Antoun
09:25 - 09:50	Défis De L'aspergillose Invasive Chez Les Patients Non Neutropéniques	Olivier Brugière
09:50 - 10:15	Aspergillose Chronique chez un Patient Immunocompétent: Est-ce Différent?	Cendrine Godet

10:15 - 10:30 Pause-Café

10:30 - 11:15 Nouvelles Perspectives dans la Gestion de la Fibrose Pulmonaire Idiopathique
Symposium Sponsorisé par Boehringer Ingelheim

Imad Bou Akl

11:15 - 12:30 Mises à Jour dans la Médecine du Sommeil

Modérateurs: Dani Abou Abdallah - Marie-Louise Coussa Koniski
Jamal Kabbani - Franck Soyez

11:15 - 11:40	SASO et Répercussions Cardiovasculaires	Martino Pengo
11:40 - 12:05	Différences de Sexe dans les Troubles Respiratoires du Sommeil	Ghada Bourjeily
12:05 - 12:30	Phénotypes de l'Apnée du Sommeil	Martino Pengo

12:30 - 12:55 Cérémonie d'Ouverture

Hymne National
Maître de Cérémonie
Dr. Celine Baaklini

12:30 - 12:35 Discours du Président de SLP

Dr. Salah Zeineldine

12:35 - 12:40 Discours du Président de AFLP

Dr. Richard Timery

12:40 - 12:45 Discours du Représentant de la SPLF

Dr. Franck Soyez

12:45 - 12:50 Discours du Président de L'Ordre Libanais des Médecins

Prof. Raymond Sayegh

12:50 - 12:55 Discours du Président de la République Libanaise

Général Michel Aoun



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**

LE **CONGRES ANNUEL 2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

VENDREDI 03 MAI, 2019

12:55 - 13:45 Session Plénière

Modérateur: Najat Saliba

12:55 - 13:45 Le Probleme Croissant de la Pollution de l'air
et sa Repercussion sur notre Santé:
Evidences Scientifiques

Mazen Malkawi
Hyam Mallat
Issam Lakkis
Tharwat Mokalled
Zeina Aoun

13:45 - 14:45 Pause Déjeuner

Modérateur: Celine Baaklini

14:45 - 15:30 Le BON choix pour le BON Patient:
Prise en Charge de la BPCO Basée sur les Preuves
Symposium Sponsorisé par GlaxoSmithKline

Elvis Irusen

15:30 - 17:10 Maladie Thromboembolique

Modérateurs: Pierre Edde - Paul Morin - Jamal Omeiss - Carole Youakim

15:30 - 15:55 Embolie Pulmonaire Massive: Options Diagnostiques et
Thérapeutiques

Francis Couturaud

15:55 - 16:20 Angioplastie et Endarteriectomie pour la Prise en
Charge des Hypertensions Pulmonaires
Thromboemboliques Chroniques (HTP TEC)

Elie Fadel

16:20 - 16:45 Endartériectomie: Expérience Libanaise

Jamil Borgi

16:45 - 17:10 CTEPH, Quelles sont les Options Thérapeutiques
Médicales?

Olivier Sitbon

Modérateur: Imad Bou Akl

17:10 - 18:10 HTAP: Rester en Avance sur la Progression de la Maladie
Symposium Sponsorisé par Actelion

Olivier Sitbon

18:10 - 18:25 Pause-Café

18:25 - 19:40 Expérience Personnelle dans les Troubles de Sommeil et l'Insuffisance Respiratoire

Modérateurs: Samir Challita - Kamel Falha - Bernard Pigearias

18:25 - 18:50 La Télémédecine dans la Médecine du Sommeil

Fayssal El Husseini

18:50 - 19:15 Masques Parlants chez les Patients Ventilés:
Etude Prospective

Moussa Riachi

19:15 - 19:40 Enquête sur les Troubles de Sommeil à Beyrouth

Hassan Chami



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**
LE CONGRES ANNUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

SAMEDI 04 MAI, 2019

08:30 **Inscription**

09:00 - 10:15 **Effet du Tabagisme sur la Santé**

Modérateurs: Antoine Abou Samra - Francis Khoury - Ali Akil

09:00 - 09:25 Prévalence de l'Usage de la Shishah, ses Méfaits, et le Rima Nakkash
Cadre Nécessaire pour le Reglementer

09:25 - 09:50 E Cigarettes et autres Alternatives Ahmad Husari

09:50 - 10:15 Tabagisme et Grossesse Ghada Bourjeily

Modérateur: Celine Baaklini

10:15 - 11:00 SPIOLTO: Carole Youakim
Soins Avancés en BPCO Basés sur des Racines Fortes
Symposium Sponsorisé par Boehringer Ingelheim

11:00 - 11:15 **Pause-Café**

11:15 - 12:30 **Asthme et Maladies de la Prématurité: Une Vue à Vol d' Oiseau**

**Modérateurs: Adèle Gemayel - Carla Irani - Richard Timery
Paul Henry Torbey**

11:15 - 11:40 Asthme chez l'Adolescent Alia Bazyzy-Asaad

11:40 - 12:05 Asthme et Obésité Joe Zein

12:05 - 12:30 Résultats Pulmonaires chez les Adultes Nés Prématurés Alia Bazyzy-Asaad

Modérateur: Zeina Aoun

12:30 - 13:15 Nouveautés dans le GOLD 2019: Application sur la Prise Marc Miravitlles
en Charge des Patients Atteints de BPCO
Symposium Sponsorisé par Novartis

13:15 - 14:15 **Pause Déjeuner**

Modérateur: Mireille Sfeir

14:15 - 15:00 Changer de Paradigm dans la Prise en Charge de Elvis Irusen
l'asthme: Que Nous Dissent les Preuves?"
Symposium Sponsorisé par GlaxoSmithKline



THE **2019 ANNUAL MEETING**
OF THE **LEBANESE PULMONARY SOCIETY**
LE **CONGRES ANNUEL 2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

SAMEDI 04 MAI, 2019

15:00 - 16:40 Session sur le Cancer du Poumon

**Modérateurs: Samer Abi Khalil - Rabih Abou Shami - Youssef ElFar
Ola Mazboudi**

15:00 - 15:25	Dépistage du Cancer du Poumon: Qu'avons-Nous Appris?	Georges Juvelekian
15:25 - 15:50	Gestion et Suivi des Nodules Pulmonaires	Carine Harmouche
15:50 - 16:15	Immunothérapie dans les CPNPC Métastatiques	Fadi El Karak
16:15 - 16:40	Préoccupations, Interactions et Facteurs Interferant avec l'Efficacité de l'Immunotherapie en General	Arafat Tfayli

16:40 - 16:55 Coffee Break

16:55 - 18:05 Lancement de la Session du Registre National

16:55 - 17:10	Lancement du Registre National sur l'Hypertension Artérielle Pulmonaire	Imad Bou Akl
17:10 - 17:25	Lancement du Registre National des Maladies Interstitielles	Georges Dabar
17:25 - 17:35	Lancement du Registre National de la MPOC	Hilmi Darwiche
17:35 - 18:05	Diskinesia Ciliaire Primaire National et Lancement du Registre	Rim Hjeij

SESSION PARALLÈLE

SALLE B

16:55 - 18:05 Discussions sur la Meilleure Affiche

18:05 - 18:25 Annonce du Prix et Clôture du Congrès



THE **2019** ANNUAL MEETING
OF THE LEBANESE PULMONARY SOCIETY
LE CONGRES ANNUEL **2019**
DE LA SOCIETE LIBANAISE DE PNEUMOLOGIE



May 2 - 4, 2019
Phoenicia Hotel, Beirut - Lebanon

Registration Information

▪ LPS Members	Free Including Lunch
▪ Non LPS Members (Lebanese)	Free Excluding Lunch
▪ International participants	\$400

The Lebanese Pulmonary Society
 Would Like to Thank the Below Sponsors
 for Their Contribution to the Success of the Congress



Organized by:
Infomed
 INTERNATIONAL FOR EVENTS

LEBANON
 4th Floor, Qubic Center
 Daoud Ammoun Street
 Horsh Tabet - Sin El Fil
 P.O. Box: 90-361 Beirut
 Tel: +961 1 510880/112/3
 Mobile: +961 71 103123

UAE
 DMCC Business Centre
 Almas Tower
 Jumeirah Lakes
 Dubai, United Arab Emirates
 Unit No: 3820
 Mobile: +971 50 9110475

infomed@infomedweb.com | www.infomedweb.com





See the difference when you

DON'T HOLD BACK

Start with **Anoro Ellipta**



ANORO[™] ELLIPTA[™]
62.5/25 mcg
Inhalation Powder
**umeclidinium/
vilanterol**

30

30 0127212

Common side effects: Sinusitis, Nasopharyngitis, Pharyngitis, Upper respiratory tract infection, Cough, Oropharyngeal pain, Constipation, Dry mouth, Urinary tract infection.

ANORO ELLIPTA (umeclidinium/vilanterol) Prescribing information for use in Near East based on GSK Version Number 03 (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) **ANORO ELLIPTA**[™] (umeclidinium/vilanterol) Inhalation powder, pre-dosed unit-dose delivered dose (the dose being the maximum of the inhaler) contains 55 micrograms umeclidinium (equivalent to 62.5 micrograms umeclidinium powder) and 25 micrograms vilanterol (as bromide). This corresponds to a pre-dosed dose of 62.5 micrograms of umeclidinium (equivalent to 62.5 micrograms umeclidinium powder) and 25 micrograms vilanterol (as bromide). Each pre-dosed unit-dose (which contains 100 µg powder) (20 mg/mg) has a mean particle size (µm) of 5.0. Magnesium sulfate heptahydrate (Umeclidinium/Vilanterol) is indicated for maintenance bronchodilator treatment to relieve symptoms associated with chronic obstructive pulmonary disease (COPD), dosage and Administration (Pharmacokinetics): The recommended and maximum dose is one inhalation of umeclidinium/vilanterol 62.5/25 micrograms once daily, at the same time each day. Children Use in patients less than 18 years of age is not relevant given the indication for this product. **Caution:** No dosage adjustment is required in patients over 65 years (see Pharmacokinetics – Special Patient Populations – Renal impairment). No dosage adjustment is required in patients with renal impairment (see Pharmacokinetics – Special Patient Populations). **Method of Administration:** Umeclidinium/Vilanterol is for oral inhalation only. **Contraindications:** Umeclidinium/Vilanterol is contraindicated in patients with severe, life-threatening allergy. **Warnings and Precautions:** The use of umeclidinium/vilanterol has not been studied in patients with asthma, and is not recommended in this patient population. Umeclidinium/Vilanterol is intended for the maintenance treatment of COPD. It should not be used for the relief of acute symptoms, such as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting bronchodilator. Frequent use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician. As with other inhalation therapies, administration of umeclidinium/vilanterol may produce occasional bradycardia, that may be life threatening. Treatment with umeclidinium/vilanterol should be discontinued if patients experience excessive and/or alternative therapy indicated if necessary. **Cardiovascular effects:** such as cardiac arrhythmias, e.g. atrial fibrillation and bradycardia, may be seen with the administration of sympathomimetic agents and muscarinic receptor antagonists, including umeclidinium/vilanterol. Therefore, umeclidinium/vilanterol should be used with caution in patients who have severe cardiovascular disease. Concurrent with its anticholinergic activity, umeclidinium/vilanterol should be used with caution in patients with narrow-angle glaucoma or urinary retention. **Interactions:** Interaction with beta-blockers (beta-adrenergic blockers) may weaken or antagonize the effect of beta-agonists, such as vilanterol. Concurrent use of other non-selective or selective beta-agonists. Caution should be provided unless there are compelling reasons for their use. Caution is advised when administering with strong CYP2C19 inhibitors as there is potential for an increased systemic exposure to vilanterol, which could lead to an increase in the potential for adverse reactions. **Induction and Inhibition:** Umeclidinium/Vilanterol should be used, taking into account the benefit of bronchodilation for the patient and the benefit of therapy for the woman. **Adverse Reactions:** Common side effects: Urinary tract infection, sinusitis, nasopharyngitis, pharyngitis, upper respiratory tract infection, cough, oropharyngeal pain, constipation, dry mouth, bronchitis, sore throat, influenza-like illness, supraventricular tachycardia, tachycardia. **Use in pregnancy:** If ovulation occurs, the patient should be treated supportively with appropriate monitoring as necessary. **ANORO, VILANTEROL, ELLIPTA** and **ELLIPTA** are trademarks of the GlaxoSmithKline group of companies. Abbreviated Prescribing Information was prepared on 07-August-2016, from GSK Version Number 03. Date of issue: 11-April-2014.

All patient pictures and quotes in this presentation are for illustrative purposes only.

Trade marks are owned by or licensed to the GSK group of companies © 2019 GSK group of companies or its licensors

For full prescribing information please refer to data sheet or contact: GlaxoSmithKline, Gulf & Near East, P.O.Box 50119 Dubai, United Arab Emirates.

For adverse events reporting of any GSK products, kindly call: LEBANON (+961 1 335268) or via ne.safety@gsk.com

March 2019

INNOVIVA

ANORO ELLIPTA[™]
umeclidinium/vilanterol

NEUCV0007/19

Grasping every opportunity, not gasping for air

.39% fewer severe exacerbation¹

.25% lower mean ICS dose¹

• Symbicort works as fast and effectively as salbutamol²

Symbicort (Turbuhaler®; 160/4.5 µg - 320/9 µg/dose budesonide/formoterol inhalation powder. Composition: budesonide 160 micrograms - 320 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms - 9 micrograms/inhalation. Excipient: Lactose monohydrate 730 micrograms per dose. Therapeutic indications: Asthma: Symbicort is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long acting β₂-agonist) is appropriate. COPD: symptomatic treatment of patients with severe COPD (FEV₁ <50% predicted normal and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators, tiotropium, and method of administration: Asthma: Symbicort® is not intended for the initial management of asthma. The dosage of the components of Symbicort® individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination products is initiated but also when the maintenance dose is adjusted. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. For Symbicort® there are two treatment approaches: A: Symbicort® maintenance therapy: Adults (18 years and older): 1-2 inhalations twice daily. Some patients may require up to a maximum of 4 inhalations twice daily. Adolescents (12-17 years): 1-2 inhalations twice daily. Children (6 years and older): A lower strength is available for children 6-11 years. B: Symbicort® maintenance and reliever therapy (only Symbicort® 80 µg & 160 µg): Adults (18 years and older): The recommended maintenance dose is 2 inhalations per day, given either as one inhalation in the morning and evening or as 2 inhalations in either the morning or evening. Children and adolescents under 18 years: Symbicort® maintenance and reliever therapy is not recommended for children and adolescents. General information: An increased exposure can be expected in patients with severe liver cirrhosis. COPD recommended doses: Adults: 2 (1 inhalation twice daily) 1 (2 inhalations twice daily). Contraindications: Hypersensitivity (allergy) to budesonide, formoterol or lactose (which contains small amounts of milk protein). Special warnings and precautions for use: It is recommended that the dose is tapered when the treatment is discontinued and should not be stopped abruptly. If patients find the treatment ineffective, or exceed the highest recommended dose of Symbicort®, medical attention must be sought. Sudden and progressive deterioration in control of asthma or COPD is potentially life threatening and the patient should undergo urgent medical assessment. Long acting β₂ adrenergic agonist (Formoterol) products: Increase risk of life threatening asthma episodes or asthma related deaths in patients taking these products. Patients should be advised to have their rescue inhaler available at all times. Patients should be reminded to take their Symbicort® maintenance dose as prescribed, even when asymptomatic. Patients should not be inhaled on Symbicort® during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma. Serious asthma-related adverse events and exacerbations may occur during treatment with Symbicort®. As with other inhalation therapy, paradoxical bronchospasm may occur, with an immediate increase in wheezing after dosing. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. Potential effects on bone density should be considered particularly in patients on high doses for prolonged periods that have coexisting risk factors for osteoporosis. If there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy, care should be taken when transferring patients to Symbicort® therapy. To minimise the risk of oropharyngeal candida infection the patient should be instructed to rinse their mouth out with water after inhaling the maintenance dose. Concomitant treatment with itraconazole, ritonavir or other potent CYP3A4 inhibitors should be avoided. Symbicort® should be administered with caution in patients with thyrotoxicosis, pheochromocytoma, diabetes mellitus, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm or other severe cardiovascular disorders, such as ischaemic heart disease, tachyarrhythmias or severe heart failure. Caution should be observed when treating patients with prolongation of the QTc interval. Formoterol itself may induce prolongation of the QTc interval. The need for, and dose of inhaled corticosteroids should be re-evaluated in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways. Concomitant treatment of β₂-agonists with drugs which can induce hypokalaemia or potentiate a hypokalaemic effect, e.g. xanthine-derivatives, steroids and diuretics, may add to a possible hypokalaemic effect of the β₂-agonist. As for all β₂-agonists, additional blood glucose controls should be considered in diabetic patients. Symbicort® Turbuhaler® contains lactose (c1 mg/inhalation). This amount does not normally cause problems in lactose intolerant people. Interactions: β₂-adrenergic blockers can weaken or inhibit the effect of formoterol. Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine), monoamine oxidase inhibitors and tricyclic antidepressants can prolong the QTc interval and increase the risk of ventricular arrhythmias. In addition L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards β₂ sympathomimetics. Concomitant treatment with monoamine oxidase inhibitors including agents with similar properties such as furazolidone and procarbazine may precipitate hypertensive reactions. There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons. Concomitant use of other β₂ adrenergic drugs can have a potentially additive effect. Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides. Budesonide and formoterol have not been observed to interact with any other drugs used in the treatment of asthma. Pregnancy and lactation: During pregnancy, Symbicort® should only be used when the benefits outweigh the potential risks. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used. Budesonide is excreted in breast milk. However, at therapeutic doses no effects on the nursing child are anticipated. It is not known whether formoterol passes into human breast milk. Undesirable effects: The most common drug related adverse reactions are pharmacologically predictable side-effects of β₂-agonist therapy, such as tremor and palpitations. Systemic effects of inhaled corticosteroids may occur particularly at high doses prescribed for prolonged periods. Infections and infestations: Common: Candida infections in the oropharynx. Nervous system disorders: Common: Headache, tremor. Respiratory, thoracic and mediastinal disorders: Common: Mild irritation in the throat, coughing, hoarseness. Treatment with β₂ agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies. Pharmacodynamic properties: Formoterol: The bronchodilating effect is dose dependent, with an onset of effect within 1-3 minutes. The duration of effect is at least 12 hours after a single dose. Special precautions for storage: Do not store above 30° C. Keep the container tightly closed. Date of revision of text: Nov 2008. Symbicort® is a trademark of the AstraZeneca group of companies.

References

1. Kunu P et al. Int J Clin Pract 2007; 61(5): 725-736.
2. Balanag VM et al. Pulmon Pharmacol & Ther 2006; 19: 139-147.

AstraZeneca Near East (NE)

Suwayh, BLDG 19 Addeh/Alheem Al-Haj Mohammad street, PO Box 17288

Zip Code 11195 Amman-Jordan Tel. +9626827580

For Adverse Events reporting please send directly to patientsafetyne@astrazeneca.com

Or contact our office on tel: +9626827580, +961 1383647